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Will Intravascular OCT Shed Light on Vascular Biology?*
Hiram G. Bezerra, MD, PHD, Marco A. Costa, MD, PHD
Cleveland, OhioThe regulatory imperatives of contemporary medi-
cine require extensive pre-clinical and clinical in-
vestigations to properly evaluate the risks and ben-
efits of novel therapies. Yet, it was only after
hundreds of thousands of devices had been im-
planted in humans that we “discovered” the inade-
quate vascular healing associated with deployed
drug-eluting stents (DES) (1). The reason for our
delay in understanding the vascular response to
DES is multifactorial, but certainly in part centers
on the limitations of the available tools to assess
mechanisms of rare events. Current in vivo imaging
technologies are inadequate to assess DES, and
investigators have had to rely on limited ex vivo data
(1,2). Furthermore, differences in the chronology of
biological processes among species pose significant
challenges to translating pre-clinical results to hu-
mans (3).
See page 76
The report from Murata et al. (4) in this issue of
iJACC offers further assurance of the capabilities of
optical coherence tomography (OCT) to provide in
vivo imaging with a near histological level of reso-
lution. Together with previous observations in dif-
ferent animal models (5), the present data help to
define a turning point in vascular device investiga-
tions. The study demonstrated the accuracy of
OCT compared with histology to detect and quan-
tify neointimal hyperplasia in various DES plat-
forms implanted in pig coronary arteries.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
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Johnson & Johnson.Murata et al. (4) found high degrees of correla-
tion with tissue histopathological specimens, using
the first generation of the time-domain OCT sys-
tem. Not surprising was the finding of discrepancies
among methods. First, the coregistration between
OCT images and histological cross sections is a
challenging process in itself. The gold-standard
method, histopathology, also has limitations that
must be acknowledged. Currently, the most fre-
quently used method consists of embedding the
sample in plastic followed by different sectioning
techniques. Tissue loss is significant with the saw
and grinding technique, whereas sectioning arti-
facts, such as folding, are more frequent with the
rotary microtome technique (6). The operational
characteristics and physics of the first generation
time-domain OCT system used in the Murata et al.
study (4) also have limitations. The small profile
(0.019-inch) of the ImageWire (LightLab Imaging
Inc., Westford, Massachusetts) makes it more
prone to eccentric intraluminal position or angula-
tion relative to the axis of the blood vessel, which
may result in imaging artifacts and overestimation
of the cross-sectional area. Another important fac-
tor that may affect the accuracy of OCT measure-
ments is the image calibration (Z-offset) process.
We have shown that a 1% change in the Z-offset
value may introduce an 14% error of area mea-
surement. The calibration must be systematically
corrected along the entire pullback and is best
performed in a frame where the catheter is in direct
contact with the vessel wall because the transparent
sheath is not always well visualized.
The new frequency-domain OCT systems such
as the C7 XR LightLab (LightLab Imaging Inc.)
provide very rapid image sampling (100 frames/s),
which allows pullback rates of up to 20 mm/s
compared with maximum 3 mm/s with the previous
generation of systems. One should expect that these
enhanced imaging capabilities together with a large
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86atheter profile having a more central intraluminal
rientation will minimize the effects of cardiac
otion and other artifacts. Obviously, the new
requency-domain OCT systems will need to be
crutinized in carefully conducted validation stud-
es, such as the present one.
After analyzing 3,000 struts, Murata et al. (4)
emonstrated the ability of OCT to appropriately
dentify uncovered stent struts, which has been pos-
ulated as the best morphometric predictor of stent
hrombosis (7). These are timely observations because
he need for a robust in vivo surrogate imaging end
oint of arterial healing is mounting. The old contro-
ersy regarding the safety of DES in the setting of
cute myocardial infarction (AMI) (8,9) is likely to
ontinue because no single clinical study has been
ufficiently powered to address the important question
f DES thrombosis in AMI, and necropsy data carry
natural inclusion bias and limited sample size. The
est available histopathological data on AMI DES
hrombosis is limited to a few patients, with analysis of
nly a small number of cross sections per patient (10).
ecently, we conducted 2 DES clinical trials using
CT as a primary imaging modality in the AMI
opulation, OCTAMI (OCT-Acute Myocardial In-
arction) (11) andHORIZONS-OCT (Harmonizing
utcomes with Revascularization and Stents in AMI)
12). The rate of uncovered struts ranged from 1% to
% of total struts compared with much higher rates
eported in histopathological data (10). The OCT
ata included a total of 50,000 struts analyzed at
.06-mm intervals compared with a few hundred
truts at 1- to 3-mm cross-sectional intervals assessed
y histology (7). Of note, uncovered DES struts are
eterogeneously distributed throughout the stent, and
heir accurate quantification requires higher analysis
ampling rates (13). Most importantly, the aforemen-
ioned OCT findings of the low frequency of uncov-
red DES struts are in accordance with the favorable
linical outcomes reported in a recent meta-analysis
9) and a large randomized trial (14).
Stent malapposition is another important factor
o consider in post-DES assessment because it has2. Sousa JE, Costa MA, Farb A, et al.
et al. Actinomycin
coronary revascularaucity of data on the histopathological assessment
f malapposition, and this was not assessed in the
urrent report. Tissue shrinkage and pressure fixa-
ion hinder histology’s ability to accurately quantify
tent malapposition. Conversely, individual strut-
evel malapposition can be quantified by OCT in
ivo and is apparently more accurate than intravas-
ular ultrasound (16). In vivo imaging also offers the
bility to perform serial analyses and differentiate
ersistent from acquired stent malapposition, which
ay have different mechanisms and prognoses (17).
Whether the gap in our understanding of vascular
ealing after DES would have been bridged much
ooner had higher resolution in vivo imaging been
reviously available remains unknown. However, var-
ous contemporary device clinical trials are integrating
CT as a primary imaging tool and considering strut
overage and malapposition as important, if not pri-
ary, surrogate end points (12,18–23). As this report
llustrates well, OCT represents a major advance in
ur interventional armamentarium, offering the clini-
ian and the investigator a unique translational imag-
ng tool. One should also expect histopathological
echniques to evolve, offering better tissue preserva-
ion, higher sampling rates with 3-dimensional recon-
truction (24), and perhaps identification of endothe-
ial prothrombotic phenotypes (25). The present
eport provides signs of a brighter future for vascular
iology investigations. However, future studies should
ocus on the complementary role rather than on
omparison of methods because advanced histology
echniques and in vivo high-resolution imaging syn-
rgistically provide the fundamental tools to fuel
iscoveries of novel cardiovascular drug and device
herapies.
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